Acumen Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Acumen Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($121.34M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($102.33M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($52.37M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($42.86M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($100.61M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($7.33M) | Mar 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($123.83M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($114.02M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($61.14M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($45.24M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($19.58M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($7.91M) | Mar 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.89M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $93.80M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $42.32M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $32.36M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $12.31M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $8.00M | Mar 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($115.54M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($86.22M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($43.06M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($35.15M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($17.96M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($7.45M) | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.83M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $238.99M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $310.13M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $196.59M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $230.33M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $44.43M | Mar 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.40M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $57.18M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $43.15M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $7.81M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $5.15M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $6.37M | Mar 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.43M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $181.82M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $266.97M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $188.78M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $225.18M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | ($18.59M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | ($11.42M) | Mar 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($446.46M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($325.13M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($222.80M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($170.43M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($127.57M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($26.97M) | Mar 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.99M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $35.63M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $66.89M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $130.10M | Mar 26, 2024 |
| FY2021 | Dec 31, 2021 | $122.16M | Mar 28, 2022 |
| FY2021 | Dec 31, 2020 | $43.78M | Mar 28, 2022 |
| FY2021 | Dec 31, 2019 | $6.55M | Mar 28, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.40M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $29.42M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $29.90M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 26, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 27, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 27, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 60.58M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 60.09M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 57.91M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 41.03M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 40.47M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 419,124 | Mar 28, 2022 |